Effect of Ocrelizumab on Gray Matter Pathology, Leptomeningeal Inflammation and Cognitive Dysfunction in Multiple Sclerosis
Latest Information Update: 14 Mar 2022
At a glance
- Drugs Ocrelizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 09 Mar 2022 Status changed from recruiting to completed.
- 28 Sep 2021 Planned primary completion date changed from 1 Apr 2021 to 1 Dec 2021.
- 15 Apr 2019 Planned End Date changed from 1 Jan 2019 to 1 Dec 2021.